Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions. Bifurcation lesions account for approximately 20 percent of all percutaneous coronary interventions (PCI).[i] The Bifurcation Cohort, part of the RESOLUTE ONYX Post-Approval Study, will include patients with coronary artery disease (CAD) receiving the Resolute Onyx DES in sizes ranging from 2–5 mm in diameter.

May 25, 2018 — Data from the first-in-human study using pulsed electric field (PEF) energy ablate heart tissue in the treatment atrial fibrillation shows very positive evidence and may usher in a new era of tissue-specific, ultra-rapid ablation. This was according to researchers presenting this late-breaking study at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. According to Abbott, Tendyne is the first and only mitral replacement valve that is repositionable and fully retrievable to allow for more precise implantation, helping improve patient outcomes. The trial is the largest study of a transcatheter mitral valve replacement device to date. Results at 30 days demonstrated that Tendyne is associated with a significant reduction of mitral regurgitation symptoms and low mortality rates.

Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest generation of the company's Xience everolimus-eluting coronary stent system. Design and technology advances in this generation of the device include features specifically designed for the treatment of complex blockages that now account for up to 70 percent of cases.

Complex Interventional Cardiovascular Therapies (CICT)

Heart Valve Summit (ACC/AATS)

 Medical, Surgical and Interventional Decision Making conference, jointly sponsored by the ACC and AATS.

As an attendee you will engage in discussions, debates and potential controversies surrounding real-world cases with renowned faculty on the cutting edge of clinically relevant data for valvular heart disease management.

Course highlights include:

Syncope with bifascicular block may be caused by intermittent complete heart block, but competing diagnoses may coexist. A new study tested whether a strategy of empiric permanent pacing (PM) reduces major adverse events more effectively than acting on the results of an implantable cardiac monitor (ICM). Results of the study were presented at Heart Rhythm 2018, the 39th annual scientific sessions of the Heart Rhythm Society (HRS), May 9-12 in Boston.

New clinical study results demonstrate that an investigational algorithm, utilizing the accelerometer signal in the Medtronic Micra Transcatheter Pacing System (TPS) may restore AV synchrony. This would improve cardiac function in patients with sinus rhythm and atrioventricular (AV) block. The results from the MARVEL (Micra Atrial TRacking Using A Ventricular AccELerometer) feasibility study were presented during a late-breaking session at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions, and simultaneously published in Heart Rhythm.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now